Effects of tourniquet use on clinical outcomes and cement penetration in TKA when tranexamic acid administrated: a randomized controlled trial

BMC Musculoskelet Disord. 2021 Jan 31;22(1):126. doi: 10.1186/s12891-021-03968-5.

Abstract

Background: The role of a tourniquet is still controversial for patients undergoing total knee arthroplasty (TKA). Our current study was performed to determine whether the nonuse of the tourniquet combine with tranexamic acid (TXA) application in TKA patients with end-stage osteoarthritis would accelerate the perioperative recovery rate and provide enough cement mantle thickness for implant fixation.

Methods: In this prospective, randomized controlled trial, 150 end-stage knee osteoarthritis patients receiving TKA were divided into three groups: group A (tourniquet group), group B (non-tourniquet group), and group C (tourniquet in cementation group). All enrolled patients received 3 g of intravenous TXA and 1 g topical TXA. The primary outcomes included blood loss variables and transfusion values. The secondary outcomes included VAS pain score, inflammatory factors level, range of motion, HSS score, postoperative hospital stay, and complication. Furthermore, by using a digital linear tomosynthesis technique, tibial baseplate bone cement mantle thickness was measured in four zones based on the knee society scoring system.

Results: No significant difference was found among the three groups with regards to total blood loss, transfusion, and complication. However, patients in group B showed lower inflammatory factors levels, shorter length of hospital stay, better range of motion, and lower postoperative pain. No significant difference was found among the three groups in four zones in terms of bone cement mantle thickness.

Conclusions: For end-stage knee osteoarthritis patients, the absence of tourniquet did not appear to affect blood loss and cement penetration in TKA patients. Furthermore, less inflammation reaction and better knee function can be achieved without a tourniquet. We recommend no longer use a tourniquet in primary TKA for patients with end-stage osteoarthritis when TXA is administrated.

Trial registration: ChiCTR-INR-16009026 .

Level of evidence: Therapeutic Level I.

Keywords: Bone cement penetration; Total blood loss; Total knee arthroplasty; Tourniquet; Tranexamic acid.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antifibrinolytic Agents*
  • Arthroplasty, Replacement, Knee* / adverse effects
  • Blood Loss, Surgical / prevention & control
  • Bone Cements
  • Humans
  • Postoperative Hemorrhage
  • Prospective Studies
  • Tourniquets
  • Tranexamic Acid*

Substances

  • Antifibrinolytic Agents
  • Bone Cements
  • Tranexamic Acid